Immuno-Oncology 2.0 Roundtable: Scientific And Pricing Challenges Can't Slow New Therapies

Scrip spoke with executives from five companies about challenges that remain for the burgeoning – but still young – immuno-oncology field in Part 2 of a wide-ranging roundtable discussion.